Summary. The effect of various compounds upon ovum transport was investigated by comparing the location of the ovum in treated and untreated subjects between 24 and 120 h following the LH peak. The 
Introduction
Since the demonstration by Burdick & Pincus in 1935 that oestrogen administration caused tube-locking of ova in mice, several reports have been published which show that ovum trans¬ port can be either accelerated or retarded in laboratory animals by provoking an excess or deficit of sex steroids or by administration of a variety of drugs. Most of the information on the subject has been reviewed at two recent symposia (Pauerstein, 1975; Harper et al, 1976) . Since then, several groups of workers have presented new data on ovum transport under the influence of hormonal changes and drug administration in rabbits (El-Banna, Sacher & Schilling, 1976; ElBanna & Sacher, 1976; Spilman, Beuving, Roseman & Larion, 1976;  Hodgson, 1976; Aref & Hafez, 1976; Tsutsumi, Takeda, Yamamoto & Tanabe, 1976; Spilman & Beuving, 1977; Takeda, Tsutsumi, Tanabe & Yamamoto, 1977; Valenzuela, Ross, Hodgson, Harper & Pauerstein, 1977) and in guinea-pigs (Maia, Salinas, Fernández & Pauerstein, 1977) .
One can infer from these observations that even if ovum transport is programmed by neuro¬ endocrine signals the programme is susceptible to modification by proper pharmacological manipulation. This being the case pharmacological modification of ovum transport becomes of interest to the physiologist as a tool to disclose the mechanisms involved in the regulation of the process. This experimental exercise is of interest also to the clinician, for it can eventually lead to the identification of compounds that can be used therapeutically to change the rate of ovum transport either for the improvement or derangement of fertility.
Methods for studying ovum transport in women have been developed recently and they have permitted us to establish the normal time course of the process (Croxatto et al, 1978a ). This in turn has been used as a base-line to assess the ability of several compounds to change the rate of transport.
This presentation is intended to review reported attempts to modify ovum transport and to describe additional unpublished observations.
Materials and Methods
Since all the procedures have been described in detail elsewhere (Croxatto et al., 1978a) , only a brief account will be given here. All During laparotomy both ovaries were inspected to identify the ovulatory side. The ipsilateral oviduct was immediately divided by means of ligatures into four segments and removed. After the other oviduct was ligated and sectioned, the uterine cavity was flushed with saline (0-15 mNaCl) by transfundal puncture. Recovery of injected fluid was not always successful and there¬ fore the number of attempts for ovum recovery from the uterus is slightly less than for ovum searches in the oviducts. Each segment of the oviduct was flushed independently and the search for ova was carried out by examining the tubai and uterine flushings in culture dishes with the aid of a dissecting microscope (x 12-25 magnification).
When the hormone assays had been completed and the segment which contained the ovum had been identified histologically, the location of the ovum was correlated with the interval from LH peak to surgery and treatment if any. Intervals from LH peak are expressed in multiples of 24 h using the sample with the highest LH concentration to identify the day of the peak. Oestrogen and progesterone levels were used to assist in resolving doubtful cases.
The following compounds were tested for their ability to accelerate ovum transport.
(1) Methyl ergonovine, 0-2 mg i.m. every 4 h, was tested in 32 subjects. The total dose administered varied from 0-6 to 4-8 mg (Guiloff et al, 1978) . (2) Ergonovine maléate (0-2 mg) plus 10 mg 4-hydroxy a-l-2-4-hydroxyphenyl ethylamino acetyl-benzyl alcohol hydrochloride (Ritodrine: Phillips-Duphar, Weesp, Netherlands) was given orally every 4 h for 4 doses in 12 subjects. (3) 15(S)15-Methyl-prostaglandin F-2a, infused i.v. at a rate of 1-5 µg/kg/h was tested in 5 subjects. The total dose varied between 216 and 500 µg (Croxatto et al, 1978b) . (4) Oestradiol-17ß, microcrystalline suspension in aqueous vehicle, given as a single dose of 5 mg i.m., was tested in 9 subjects.
Fifty-four (54) untreated subjects served as a control group (Croxatto et al, 1978a) .
Results
Details on the time relationships between the LH peak, treatment and surgery in subjects treated with oestradiol-17 ß or ergonovine plus Ritodrine have not been published before and they are presented in Table 1 . For similar details in the groups treated with methyl ergonovine or the prostaglandin, the reader is referred to the original publication cited in the text. Overall ovum recovery in control and treated subjects is shown in Table 2 . The lowest recovery rate 44%, was obtained in the control group and the highest one, 100%, was observed in the group treated with prostaglandin (PG) F-2a. The highest recovery rates in all the groups were attained when the oviducts were searched for eggs 72 h after the LH peak.
The location of ova at various intervals following the LH peak in untreated subjects is shown in Tables 3 and 4 . Up to 72 h after the LH peak the ova were recovered only from the oviduct, while at 96 h, 5 out of 6 ova were in the oviduct and one was in the uterus. After this time ova were found only in the uterus. Regardless of time of recovery, the most frequent location within the oviduct was the ampullary segment. Only 2 of the 19 ova found in the oviduct had passed beyond the ampullary-isthmic junction and these were at the latest time at which ova could be recovered from the tubes.
As shown in Tables 3 and 4 in none of the treated subjects were ova recovered from the uterus earlier than 96 h following the LH peak and within this interval the rate of recovery from the Fallopian tubes was comparable to or higher than that of the untreated control group. In one subject treated with methyl ergonovine (Table 4 ) and another treated with ergonovine plus Ritodrine (Table 4) , the ovum was recovered from the oviduct at 120 h. In each of the treated groups most of the ova recovered from the Fallopian tubes were located in the ampulla (Table 3) . Retarded transport can be inferred when ova are found in the oviducts at 120 h or later, as was found with 2 subjects, both treated with ergot derivatives, but because of the small size of the sample we cannot conclude that the treatment caused delayed transport. Nevertheless, this possibility merits further investigation.
Concerning the biological activity of the compounds tested, previous studies have shown beyond doubt that methyl ergonovine (Guiloff et al, 1978) and 15(S)15-methyl-PGF-2a (Croxatto et al, 1978b) administered in the same manner as reported here do have a lasting stimulatory effect upon human oviductal motility in vivo. The observations on ovum transport reviewed here demonstrate that the increased motility of the tube produced by methyl ergonovine or PGF-2a does not lead to accelerated ovum transport.
One possible explanation of this result is that excessive tonic stimulation of the circular muscle could be associated with further narrowing or closure of the isthmic lumen, thus preventing passage of the ovum beyond the ampullary-isthmic junction. The same mechanism could be operating also at the level of the interstitial portion of the tube because both substances have the ability to stimulate myometrial contractions. Considering this argument it was proposed (Coutinho, 1976) , that ovum transport could be accelerated if isthmic and/or myometrial muscle (Rosenblum & Stein, 1966) , and also the myometrium (Coutinho, Maia & Filho, 1974) , Ritodrine, a ß-adrenergic agonist, was chosen for this purpose. Ergonovine maléate was selected to activate rhythmic contractions because it has been shown that, at the doses used in the present study, it does stimulate tubai contractility in women (Coutinho, 1971) . Ritodrine, on the other hand, at the dose of 10 mg orally, relaxes the myometrium of the non-pregnant uterus but has little effect on the myosalpinx (Coutinho et al, 1974) . However, there are no data on the effect of these two compounds in combination, either upon the myometrium or upon the myosalpinx. This issue will have to be resolved before the present results with ergonovine and Ritodrine can be interpreted with certainty.
Post-ovulatory administration of oestrogens can disturb ovum transport in several species and each one responds in a particular fashion depending on the dose and time of administration (Croxatto & Ortiz, 1975 (Ellinger & Kirton, 1974; Spilman et al, 1976; Hodgson, 1976; Takeda et al, 1977) but not in hamsters or rats (Labhsetwar, 1972 (Labhsetwar, , 1973 or guinea-pigs (Maia et al, 1977) . Oestradiol has been shown to be active in all species tested, producing either accelerated or delayed transport, but only a single dose was tried in the women in this study and as with the other compounds the experiment was designed to give evidence only of accelerating effects. These considerations point to the fact that the task has just begun and there is much room for favourable developments.
One lesson we have learned from these results is that in choosing a compound one should bear in mind that its ability to stimulate oviductal contractility in vivo in women does not guarantee that it will accelerate ovum transport. Furthermore, this implies that we are not ready to use a simple mechanical index, such as the intraluminal pressure response to drug admini¬ stration, to predict effects upon ovum transport and that the mechanics of ovum transport are still far from being in the domain of our understanding. The present limitations could be over¬ come perhaps by the combined effort of drug screening in laboratory animals and the experi¬ mental analysis of mechanical factors involved in normal, accelerated and delayed transport.
